All In Biotech

Drug Trial Radar · NCT02203149

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

A Phase II, Randomized Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C and a Phase III, Randomized Placebo-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C

Last checked: Nov 19, 2026Latest source record: Sep 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 399 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

399

Actual

Start

Aug 1, 2014

Primary completion

Oct 2, 2015

Study completion May 16, 2016

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part study of grazoprevir (MK-5172) + elbasvir (MK-8742) in Japanese participants with chronic hepatitis C virus (HCV) genotype 1 (GT1). Part I is a dose-finding study; in Part II, participants will be randomly assigned to receive grazoprevir at the dose determined in Part I in combination with elbasvir. The primary study hypothesis is that the percentage of treatment-naïve participants in the Immediate Treatment Arm of Part II who achieve sustained viral response at 12 weeks after the end of all treatment (SVR12) will be greater than the reference rate of 75%. A separate study arm for cirrhotic participants will also be included in Part II; these participants will receive grazoprevir at the determined dose in combination with elbasvir.

Conditions

  • Hepatitis C

Interventions

  • GrazoprevirDrug

    One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.

  • ElbasvirDrug

    One 50 mg tablet taken orally once daily for 12 weeks.

  • Placebo to GrazoprevirDrug

    One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.

  • Placebo to ElbasvirDrug

    One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 2: Percentage of Treatment-naïve Participants in the Immediate Treatment Arm Achieving Sustained Viral Response at 12 Weeks After The End of All Treatment (SVR12)Time frame: 12 weeks after end of all therapy in Part 2 (Study Week 24 of Part 2)
  2. Part 1: Percentage of Participants Experiencing an Adverse Event (AE) During Treatment and First 4 Follow-Up WeeksTime frame: Up to 4 weeks post last dose in Part 1 (Up to total of 16 weeks)
  3. Part 1: Percentage of Participants That Discontinued Treatment Due to an AETime frame: Up to Study Week 12 in Part 1
  4. Part 2: Percentage of Participants Experiencing an AE During Initial Treatment and First 4 Follow-Up WeeksTime frame: Up to 4 weeks following initial treatment in Part 2 (Up to total of 16 weeks)
  5. Part 2: Percentage of Participants That Discontinued Initial Treatment Due to an AETime frame: Up to Study Week 12 in Part 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.